Expression of phospho-Akt and PTEN proteins in human breast cancer in relation to tumor progression and patient survival

Yonago Acta Medica

Volumn 49, Issue 1, 2006, Pages 19-27

  Yamamoto, Osamu ^a   Gomyo, Yoshihito ^a   Hirooka, Yasuaki ^a   Tsujitani, Shunichi ^a   Ikeguchi, Masahide ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Breast cancer; Immunohistochemistry; Phosphatase and tensin homolog detected on chromosome ten; Phosphorylated Akt; Prognosis

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL KINASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

EID: 33645333934     PISSN: 05135710     EISSN: 05135710     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Andjelkovic M, Alessi DR, Meier R. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997;272:31515-31524.
2. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-3997.
3. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602.
4. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Nakshatri H. Phophatidylinositol 3-kinase /AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
5. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffausen BS, Cantley LC. Purificatin and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 1990;265:19704-19711.
6. Chan TO, Rittenhouse SE , Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinase: kinase activation by phosphoinostitide- dependent phosphoryylation. Annu Rev Biochem 1999;68:965-1014.
7. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-717.
8. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemming BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (Lond.) 1995;378:785-789.
9. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
10. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14:672-676.
11. Franke TF, Kaplan DR, Cantley LC, Toxer A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol 3,4-bisphosphate. Science 1997;275:665-668.
12. Gingras AC, Kennedy SG, O,Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 1998;12:502-513.
13. Hajduch E, Alessi DR, Hemming BA, Hundal HS. Constitutive activation of protein kinase Bα by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes 1998;47:1006-1013.
14. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression and cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002;94:3127-3134.
15. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 2000;60:6201-6207.
16. Kappes H, Goemann C, Bamberger AM, Loning T, Milde-Langosch K. PTEN expression in breast and endometrial cancer: correlation with steroid hormone receptor status. Pathobiology 2001;69:136-142.
17. Khwaja A, Lehmann K, Marte BM, Downward J. Phosphoinositide-3 kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J Biol Chem 1998;273:18793-18801.
18. Landis SH, Murray T, Bolden S, Wingon S. Cancer statistics. CA Cancer J Clin 1998;48:6-29.
19. Liang-Ping W, Wendy M, Charis E. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. C ancer Res 1999;59:5808-5814.
20. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8:1461-1472.
21. Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002;6:539-53.
22. Mei Sun, Gen Wang, June E Paciga, Richard I Feldman, Zeng-Qiang Yuan, Xiao-Ling Ma, et al. AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathology 2001;159:431-437.
23. Meier R, Alessi DR, Cron P. Mitogenic activation, phosphorylation, and nucler translocation of protein kinase Bα. J Biol Chem 1997;272:30491-30497.
24. Nakatani K, Thompson DA, Barthel A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Pathol 1999;274:21528-21532.
25. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NFκB activation by tumor necrosis factor requires the Akt serine-theronine kinase. Nature 1999;401:82-85.
26. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999;286:1738-1741.
27. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-205.
28. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-Morpholinyl)-8-phenylchromone (LY294002), a specific inhibitor of phsphatidylinositol 3-kinase, in human colon cancer cells. Clin Cancer Res 2002;8:1957-1963.
29. Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, et al. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 2003;104:195-203.
30. Stmad P. The 5th edition of the TNM classification malignant tumor of the breast. Cesk Gynecol 1999;64:54-57.
31. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle survival by regulating phosphatidylinositol 3,4,5-triphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999;96:6199-6204.
32. Van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998;273:13150-13156.
33. Varticovski L, Harrison-Findik D, Keeler ML, Susa M. Role of PI3-kinase in mitogenesis. Biochim Biophys Acta 1994;1226:1-11.
34. Weng LP, Smith WM, Dahia PL, Ziebold U, Gil E, Lees JA, et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 1999;59:5808-5814.
35. Zhou XP, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M, et al. Association of germline mutation in the PTEN tumor suppressor gene and Proteus and Proteus-like syndrome. Lancet 2001;358:210-211.